Qualigen Therapeutics, Inc. (QLGN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2042 Corte Del Nogal
Carlsbad, CA 92011
United States of America (the)
Phone
760 918 9165
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 23, 2015
| Name | Title | Pay | Year Born |
| Kevin A. Richardson | Co-Chief Executive Officer, Chief Accounting Officer & Chairman of the Board | 90,907 | 1968 |
| Jiawei Wang | Co-Chief Executive Officer | 0 | N/A |
| Robert W. Campbell Becher | President | 88,000 | 1970 |
| Christopher L. Lotz | Vice President of Finance & Corporate Secretary | 397,344 | 1965 |
| Michael S. Poirier | Chief Operating Officer | 686,526 | 1956 |
| Koti Meka | Chief Financial Officer | 0 | 1969 |
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.